Dow Jones
38.226,19 +322,90 (+0,85%) Nasdaq
15.840,96 +235,48 (+1,51%) Nikkei 225
38.236,07 -37,98 (-0,10%) EUR/USD
1,0731 +0,0013 (+0,12%) Bitcoin EUR
55.248,39 +2.209,59 (+4,17%) CMC Crypto 200
1.274,27 +3,53 (+0,28%)
Immuneering Corporation (IMRX)
Dopo ore:
| Chiusura precedente | 1,5300 |
| Aperto | 1,5500 |
| Denaro | 1,5300 x 200 |
| Lettera | 1,5800 x 200 |
| Min-Max giorno | 1,5100 - 1,6300 |
| Intervallo di 52 settimane | 1,3800 - 11,9200 |
| Volume | |
| Media Volume | 762.227 |
| Capitalizzazione | 46,259M |
| Beta (5 anni mensile) | -0,89 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,8800 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 13,29 |
GlobeNewswireImmuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven tumor types, including models of RAS and RAF mutant melanoma, pancreatic cancer, and lung cancer – IMM-1-104 in combination with gemcitabine or paclitaxel drove enhanced anti-tumor activity in humanized 3D-tumor growth assays across multiple pancreatic cancer models – Strength of preclinical activity da
- GlobeNewswire
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it will present preclinical data on IMM-1-104, its lead clinical-stage program, and IMM-6-415 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston. Detail
- GlobeNewswire
Immuneering to Present at the Morgan Stanley Healthcare Conference
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Morgan Stanley Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M
